GlassScriptPhysician profile
Hector De Leon
NPI 1821023268
$4,805.68
in general payments reported to CMS, 2019-2025
32 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $386 · 2021: $724 · 2022: $862 · 2023: $841 · 2024: $707 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $555.63 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $513.71 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $428.10 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $404.18 | 2019-2025 | Ingrezza |
| Abbvie INC. | $363.82 | 2021-2025 | Vraylar |
| Tris Pharma INC | $314.03 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $301.19 | 2022-2025 | Azstarys |
| Lundbeck LLC | $261.61 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.63 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $169.34 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $135.60 | 2019-2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $125.13 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $94.28 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $87.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.02 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $82.81 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $77.48 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $74.36 | 2022-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $72.66 | 2022-2024 | Quviviq |
| Alkermes, INC. | $68.11 | 2021-2025 | Lybalvi, Aristada |
| Collegium Pharmaceutical, INC. | $62.89 | 2025 | Jornay Pm |
| Neuronetics, INC. | $58.09 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $51.98 | 2025 | Equetro, Raldesy |
| Teva Pharmaceuticals USA, INC. | $44.94 | 2022-2023 | Austedo Xr |
| Shire North American Group INC | $39.44 | 2019 | |
| Noven Therapeutics, LLC | $33.23 | 2024-2025 | Xelstrym |
| Neos Therapeutics, LP | $16.88 | 2020 | |
| Bausch Health US, LLC | $15.90 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.50 | 2019 | |
| Allergan, INC. | $13.96 | 2020 | |
| Adlon Therapeutics L.P. | $12.55 | 2021 | |
| Alfasigma USA, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.